Bladder cancer test kit NMP22®
urineenzyme immunoassay

bladder cancer test kit
bladder cancer test kit
Add to favorites
Compare this product
 

Characteristics

Applications
bladder cancer
Sample type
urine
Analysis mode
enzyme immunoassay

Description

The Alere NMP22® Test Kit is an enzyme immunoassay (EIA) for the in vitro quantitative determination of the nuclear mitotic apparatus protein (NuMA) in stabilized voided urine. NuMA is an abundant component of the nuclear matrix proteins (NMP22). BENEFITS Nuclear Matrix Protein 22 (NMP22) is a common protein found in the nucleus of all cells. Bladder cancer cells release NMP22 into urine. Even at the earliest stages of the disease, elevated levels of NMP22 can be detected using an NMP22-specific assay, making it a marker for early diagnosis and monitoring in conjunction with standard diagnostic procedures.1 Early detection of Bladder Cancer is the key to improving chances of survival. Our test is an adjunct to cystoscopy and improved the combined detection rate for Bladder Cancer and had in general better sensitivity compared to cytology.2

Catalogs

No catalogs are available for this product.

See all of Abbott‘s catalogs

Other Abbott products

PRODUCT CATALOG

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.